Subject: PMCB is on High Alert Today!

BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
SCV Client Spotlight

Check out SmallCapVoice on Facebook, Twitter and YouTube!
Follow or Like Us today!
Put PMCB on Your Radar Today!

PharmaCyte Biotech, Inc.
12510 Prosperity Drive
Suite 310
Silver Spring, MD 20904
Facebook Twitter


PMCB recently reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies for the treatment of diabetes. The publication, titled "The use of ß-cell transcription factors in engineering artificial ß cells from non-pancreatic tissue," which was authored by a member of PharmaCyte Biotech's Diabetes Consortium, Prof. Ann M. Simpson and her colleagues at UTS, appeared in the prestigious Nature publishing group scientific journal Gene Therapy. This review can be located by clicking here.

The article reports that cell and gene therapies have shown promise as a potential cure for Type 1 diabetes through the genetic engineering of non-pancreatic cells that makes them capable of regulating blood glucose levels by producing insulin on demand. Such genetic modification and augmentation of non-pancreatic cells has the ultimate goal of producing glucose-responsive "artificial" ß insulin-producing cells that mimic the function of pancreatic ß cells in non-diabetic individuals.

Using some of the technology discussed in the review article, Prof. Simpson and her colleagues have developed the Melligen cell line, a human non-pancreatic cell line that originated from liver cells that were genetically engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body. The Melligen cell line is currently undergoing an initial evaluation for its utility in PharmaCyte Biotech's Cell-in-a-Box(R)-based treatment of diabetes, the first of a number of preclinical studies that will be performed by PharmaCyte Biotech's international Diabetes Consortium.

Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are delighted by this important publication from one of the key members of our international Diabetes Consortium. Prof. Simpson is a world-renowned scientist in the field of diabetes and, as this publication shows, is at the forefront of research into finding a cure for this disease."

Recent Highlights:

  • The first preclinical study by TD2 in the U.S. that deals with the effectiveness of PharmaCyte Biotech's pancreatic cancer treatment on the accumulation of malignant ascites fluid that is often associated with the growth of abdominal cancers, including pancreatic cancer, has been completed and positive results were obtained.

  • PharmaCyte Biotech has commenced the development of a clinical protocol for the planned Phase 2b clinical trial in pancreatic cancer.

  • Applications have been submitted to drug regulatory authorities in the U.S., Europe and Australia to obtain Orphan Drug status for PharmaCyte Biotech's pancreatic cancer treatment that combines Cell-in-a-Box® with low doses of the anticancer prodrug ifosfamide.

  • Contracts have been executed with major institutions that will permit the development of a diabetes treatment that combines Cell-in-a-Box® with insulin-producing cells, and a Diabetes Consortium has been established to facilitate this important research.

  • The live cell encapsulation facility in Thailand, where the Cell-in-a-Box® encapsulation will be done, has now officially opened and is an extremely important development as this facility is essential for all of PharmaCyte Biotech's efforts in developing treatments for cancer and diabetes.

  • Rapid progress is being achieved at the University of Northern Colorado in the pursuit of treatments for cancer that will combine cannabinoid-like compounds with the Cell-in-a-Box® technology.
PMCB Chart


Market Value:
95,453,362 a/o Feb 17, 2015

Shares Outstanding:
699,292,029 a/o Dec 15, 2014

529,206,849 a/o Aug 26, 2014

Authorized Shares:

1,490,000,000 a/o Aug 26, 2014

Shareholders of Record:
1,311 a/o Aug 04, 2014

Short Interest
1,343,930 (2.16%) Jan 15, 2015

Transfer Agent:
Signature Stock Transfer, Inc.


PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes

PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes


Kenneth L. Waggoner

CEO, President

Gerald W. Crabtree, Ph.D.

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications. Small Cap Voice received one thousand dollars from the company on 2-18-15 for a one day email campaign.

About Penny Stocks